TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
SNO 2023 poster: |
Press Release2024, June 18 08:00 a.m. TME Pharma announces results of successful capital increase with €2.35 million raised 2024, June 17 05:45 p.m. TME Pharma announces a financing guarantee agreement and the launch of capital increase of minimum 2.2 million euros 2024, June 17 05:30 p.m. TME Pharma announces publication in Nature Communications of biomarker data from NOX-A12 GLORIA Phase 1/2 trial in glioblastoma |
EventsBio International Convention
Dirk Eulberg, Ewelina Staniuk |